Displaying drugs 13176 - 13200 of 14517 in total
RR001
RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL).
Investigational
P-BCMA-101
P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
Investigational
Bersanlimab
Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).
Investigational
WTx-Bortezomib
Experimental
SurVaxM
Investigational
Belagenpumatucel-L (NCI H-520)
Investigational
Belagenpumatucel-L (RH 2)
Investigational
PAT-SM6
Investigational
SCH-58500
SCH-58500 is a recombinant replication-deficient adenovirus vector carrying the human p53 gene.
Investigational
VXM01
Investigational
KAHR-102
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
ERC-1671
Investigational
pM-81
Investigational
L-3972-T
L-3972-T is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.
Investigational
Mecbotamab vedotin
Mecbotamab vedotin is an anti-Axl humanized monoclonal antibody conjugated to monomethyl auristatin E using a cleavable linker (CAB-Axl-ADC).
Investigational
Serplulimab
Investigational
MK-0482
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
MK-4830
MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.
Investigational
Therapeutic allogeneic lymphocytes
Investigational
ETBX-011
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational
Interleukin-15, human recombinant
Investigational
Odetiglucan
Investigational
Displaying drugs 13176 - 13200 of 14517 in total